Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 6
2015 13
2016 20
2017 8
2018 5
2019 10
2020 3
2021 6
2022 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types.
Chowell D, Yoo SK, Valero C, Pastore A, Krishna C, Lee M, Hoen D, Shi H, Kelly DW, Patel N, Makarov V, Ma X, Vuong L, Sabio EY, Weiss K, Kuo F, Lenz TL, Samstein RM, Riaz N, Adusumilli PS, Balachandran VP, Plitas G, Ari Hakimi A, Abdel-Wahab O, Shoushtari AN, Postow MA, Motzer RJ, Ladanyi M, Zehir A, Berger MF, Gönen M, Morris LGT, Weinhold N, Chan TA. Chowell D, et al. Nat Biotechnol. 2022 Apr;40(4):499-506. doi: 10.1038/s41587-021-01070-8. Epub 2021 Nov 1. Nat Biotechnol. 2022. PMID: 34725502 Free PMC article.
TERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence.
Yu Y, Fan D, Song X, Zakeri K, Chen L, Kang J, McBride S, Tsai CJ, Dunn L, Sherman E, Katabi N, Dogan S, Cracchiolo J, Cohen M, Boyle JO, Lee M, Valero C, Wang J, Wong R, Morris L, Riaz N, Lee N. Yu Y, et al. JCO Precis Oncol. 2021 Aug 5;5:PO.20.00515. doi: 10.1200/PO.20.00515. eCollection 2021 Aug. JCO Precis Oncol. 2021. PMID: 34381934 Free PMC article.
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors.
Valero C, Lee M, Hoen D, Weiss K, Kelly DW, Adusumilli PS, Paik PK, Plitas G, Ladanyi M, Postow MA, Ariyan CE, Shoushtari AN, Balachandran VP, Hakimi AA, Crago AM, Long Roche KC, Smith JJ, Ganly I, Wong RJ, Patel SG, Shah JP, Lee NY, Riaz N, Wang J, Zehir A, Berger MF, Chan TA, Seshan VE, Morris LGT. Valero C, et al. Nat Commun. 2021 Feb 1;12(1):729. doi: 10.1038/s41467-021-20935-9. Nat Commun. 2021. PMID: 33526794 Free PMC article.
The association between tumor mutational burden and prognosis is dependent on treatment context.
Valero C, Lee M, Hoen D, Wang J, Nadeem Z, Patel N, Postow MA, Shoushtari AN, Plitas G, Balachandran VP, Smith JJ, Crago AM, Long Roche KC, Kelly DW, Samstein RM, Rana S, Ganly I, Wong RJ, Hakimi AA, Berger MF, Zehir A, Solit DB, Ladanyi M, Riaz N, Chan TA, Seshan VE, Morris LGT. Valero C, et al. Nat Genet. 2021 Jan;53(1):11-15. doi: 10.1038/s41588-020-00752-4. Epub 2021 Jan 4. Nat Genet. 2021. PMID: 33398197 Free PMC article.
65 results